Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma
This study has been completed.
Massachusetts General Hospital
Brigham and Women's Hospital
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Tracy T. Batchelor, MD, Massachusetts General Hospital
First received: January 9, 2009
Last updated: April 30, 2015
Last verified: April 2015
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||February 2015|
|Primary Completion Date:||February 2015 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Chheda MG, Wen PY, Hochberg FH, Chi AS, Drappatz J, Eichler AF, Yang D, Beroukhim R, Norden AD, Gerstner ER, Betensky RA, Batchelor TT. Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study. J Neurooncol. 2015 Feb;121(3):627-34. doi: 10.1007/s11060-014-1680-2.